Anti-infective Agents : Antiretroviral Agents
OVIRA2 “Viramune tablet” 200 mg/tab
OVIRA3 “Viramune XR tablet” 400 mg/tab
適應症：
OVIRA2：與其他藥物併用、治療免疫缺陷逐漸惡化或嚴重HIV-1感染之成年病患。
OVIRA3：VIRAMUNE持續性藥效錠適用於與其他抗反轉錄病毒藥物合併使用，以治療愛滋病毒HIV-1感染。
Usual dose:
In combination with other antiretrovirals:
Adult: (immediate-release) 200 mg qd for 14 days, then 200 mg bid. (extended-release) for patients not currently taking immediate-release, initiate with 200 mg immediate-release nevirapine qd for 14 days, followed by 400 mg extended-release nevirapine qd.
Pediatric
(neonates < 1 mon): 6 mg/kg bid.
(1 mon- < 8 yrs): 200 mg/m2 qd for 14 days then increase to bid depending on tolerability; max. 200 mg bid (immediate-release).
(≧8 yrs): 120 to 150 mg/m2 qd for 14 days then increase to bid depending on tolerability; max. 200 mg bid (immediate-release) or 400 mg qd (extended-release)
(≧6 yrs): ≧BSA 1.17 m2, currently receiving immediate-release bid, may switch to extended release without lead in dosing, 400 mg (extended-release) qd.
Perinatal transmission; prophylaxis: infants born to women with no antiretroviral therapy prior to labor, 8 mg (birthweight 1.5-2 kg)/ 12 mg (birthweight > 2 kg) for 3 doses; give first dose within the first 48 hours of birth, second dose 48 hours after first dose, and third dose 96 hours after second dose.
Contraindication:
hepatic impairment, moderate or severe (Child Pugh Class B or C)
Adverse effect:
Common: rash, any grade, lipodystrophy, diarrhea, nausea, headache, fatigue.
Serious: Stevens-Johnson syndrome, toxic epidermal necrolysis, granulocytopenic disorder, neutropenia, hepatotoxicity, anaphylaxis, hypersensitivity reaction, rhabdomyolysis.